Evolocumab
Coronary Heart Disease (CHD)
University Medical Centre Ljubljanamonoclonal_antibodyPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Coronary Heart Disease (CHD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Rajaie Cardiovascular Medical and Research Center | Phase 4 | BBB |
Ezetimibe Canadian Collaborative Research Network | Phase 4 | BBB |
Ranolazine OBS Pakistan | Phase 4 | BBB |
Rivaroxaban Sheffield Teaching Hospitals NHS Foundation Trust | Phase 4 | BBB |
SIMVASTATIN University of Washington | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Evolocumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →